Personalized Medicine: Taking Healthcare Out of the Dark Ages
| Why do some treatments work, while others fail? How many lives could be saved with the correct diagnoses and personalized treatments? Scientists are developing the technology to analyze the proteins our bodies produce at the molecular level. These biomarkers detect the presence of serious disease states such as cancer, chronic renal conditions and cardiovascular events long before they are found through traditional testing, increasing the likelihood of much better outcomes. Yet there are still human and economic obstacles to overcome before the wellness chip and a healthier new world become realities. Join us to learn more about this fascinating topic. | |||||||||||||||
| June 4th, 2010 7:00 AM - 9:00 AM | |||||||||||||||
|
Doubletree Denver Tech Center - Indigo Room
Map This Location7801 E. Orchard Rd Greenwood Village, CO 80111 |
|||||||||||||||
|
Phone:
303-265-9224 Email: customer.service@chsm.org |
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
Stephen A. Williams, M.D., Ph.D. is Chief Medical Officer for SomaLogic, Inc. Dr. Williams trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships returned to the same institution for a PhD in medicine and physiology. He subsequently performed 3 years residency in diagnostic imaging at the University of Newcastle Upon Tyne. He joined Pfizer in the UK in 1989 in Experimental Medicine, and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the USA in 1993 still at Pfizer and worked in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head-injury. He created the Clinical Technology group in 1997, which became a worldwide function on 5 research sites with the objective of validating clinical biomarkers and measurements, and was made VP in 2006. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates and guidelines for development teams to make the decision to start phase III.